miR-92a regulates TGF-β1-induced WISP1 expression in pulmonary fibrosis

Barbara Berschneider1, Daniel C Ellwanger2, Hoeke A Baarsma1

  • 1Comprehensive Pneumology Center, Helmholtz Zentrum Munchen, University Hospital, Ludwig-Maximilians University, Munich, Member of the German Center for Lung Research (DZL), Germany.

Insights

MicroRNAs regulate WNT1-inducible signaling pathway protein 1 (WISP1) in pulmonary fibrosis. Reduced miR-92a levels in idiopathic pulmonary fibrosis (IPF) patients correlate with increased WISP1, suggesting miR-92a

Area of Science:

  • Pulmonary Medicine
  • Molecular Biology
  • Genetics

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease.
  • MicroRNAs (miRNAs) are key regulators in IPF pathogenesis.
  • WNT1-inducible signaling pathway protein 1 (WISP1) is a pro-fibrotic mediator in IPF, but its regulation is unclear.

Purpose of the Study:

  • Investigate miRNA regulation of WISP1 in IPF.
  • Determine the role of miR-30a/d and miR-92a in WISP1 expression.
  • Elucidate the mechanisms underlying WISP1 dysregulation in IPF.

Main Methods:

  • Supervised machine learning to predict miRNA target sites in WISP1 3'UTR.
  • Quantitative analysis of miRNA and WISP1 expression in IPF samples and lung fibroblasts.
  • In vitro and in vivo experiments using transforming growth factor (TGF)-β1 stimulation.

Main Results:

  • miR-30a/d and miR-92a target sites were identified in the WISP1 3'UTR.
  • miR-92a and miR-30a levels were decreased, while WISP1 protein was increased in IPF.
  • TGF-β1 induced WISP1 expression, which was reversed by miR-30a and miR-92a.
  • miR-92a inhibition increased WISP1 protein expression.
  • An inverse correlation between WISP1 and miR-92a was observed in IPF fibroblasts.

Conclusions:

  • miR-92a acts as a negative regulator of WISP1 expression in pulmonary fibrosis.
  • Dysregulation of miR-92a contributes to WISP1 overexpression in IPF.
  • Targeting miR-92a may offer a therapeutic strategy for IPF.